Fagron delivers strong performance with 12% topline growth

Fagron delivers strong performance with 12% topline growth and 14% increase in REBITDA for FY 2023.

Fagron, the leading global player in pharmaceutical compounding publishes its full year results for the period ending 31 December 2023.

Key Highlights

• Strong topline performance with 11.6% reported revenue growth (12.5% at CER) and 10.5%
  organic revenue growth at CER supported by growth across all regions
• 13.9% REBITDA increase translates to 40bps REBITDA margin uplift YoY to 19.5%,
  reflecting synergies from North America acquisitions and operational excellence benefits
• Operating cash flow increases by 13.9% to €124.6 million resulting in improved leverage
  ratio of 1.4x
• Acquisition of London Specialist Pharmacy in the United Kingdom
• Dividend proposal of €0.30 per share (+20%)
• Good progress on greenhouse gas intensity reduction target
• FY ’24 outlook of high single-digit organic sales growth and continued improvement in
  profitability

Full press release